Literature DB >> 1520791

Rocky Mountain "spotless" and "almost spotless" fever: a wolf in sheep's clothing.

D J Sexton1, G R Corey.   

Abstract

In 10 (10.8%) of 93 laboratory-confirmed or probable cases of Rocky Mountain spotted fever seen at Duke University Medical Center from 1969 to 1991, illness without rash or fleeting or atypical skin eruptions were noted. Data from these 10 cases and 33 similar previously reported cases of Rocky Mountain "spotless" or "almost spotless" fever support the premise that human Rickettsia rickettsii infection has a broader spectrum than that indicated by its classic description. Sixty-one percent of patients with Rocky Mountain spotless or almost spotless fever have been men. Two-thirds have been black. Although in some cases the absence of rash may be due to the prompt institution of therapy with chloramphenicol or tetracycline, in others long delays in recognition of the disease and treatment occurred, resulting in the deaths of 53% of patients. On the basis of outcome in the cases reviewed, empirical administration of chloramphenicol or a tetracycline to selected patients is justifiable (including those patients with severe organ dysfunction), even if they have no rash, a transient rash, or a rash of unusual distribution. Indeed, without such therapy, patients with spotless or almost spotless fever may die. Recognizing such atypical cases is analogous to seeing a wolf in sheep's clothing--intuition, experience, knowledge, and a high index of suspicion are required.

Entities:  

Mesh:

Year:  1992        PMID: 1520791     DOI: 10.1093/clind/15.3.439

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Clinical manifestations of tick-borne infections in children.

Authors:  K A Bryant; G S Marshall
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

2.  Fundus Examination: A Key to Spot the Spotted Fever!

Authors:  Somashekhar Chikkanna; Sujatha Ramabhatta; Mohan Kumar; K Dhatri
Journal:  Indian J Pediatr       Date:  2016-03-05       Impact factor: 1.967

Review 3.  Atypical Rocky Mountain spotted fever with polyarticular arthritis.

Authors:  Muhammad A Chaudhry; Robert Hal Scofield
Journal:  Am J Med Sci       Date:  2013-11       Impact factor: 2.378

4.  Quantitative analyses of variations in the injury of endothelial cells elicited by 11 isolates of Rickettsia rickettsii.

Authors:  M E Eremeeva; G A Dasch; D J Silverman
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  Risk factors for fatal outcome from rocky mountain spotted Fever in a highly endemic area-Arizona, 2002-2011.

Authors:  Joanna J Regan; Marc S Traeger; Dwight Humpherys; Dianna L Mahoney; Michelle Martinez; Ginny L Emerson; Danielle M Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Velda Williams; Charlene Hamilton; Craig Levy; Ken Komatsu; David A Yost; Jennifer H McQuiston
Journal:  Clin Infect Dis       Date:  2015-02-19       Impact factor: 9.079

Review 6.  Rickettsioses as paradigms of new or emerging infectious diseases.

Authors:  D Raoult; V Roux
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

7.  Comparative value of blood and skin samples for diagnosis of spotted fever group rickettsial infection in model animals.

Authors:  Michael L Levin; Alyssa N Snellgrove; Galina E Zemtsova
Journal:  Ticks Tick Borne Dis       Date:  2016-05-26       Impact factor: 3.744

Review 8.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

9.  Rocky Mountain Spotted Fever Masquerading as Gastroenteritis: A Common but Overlooked Clinical Presentation.

Authors:  David S Braun; Ian Greenberg; Mangesh Pagadala
Journal:  Cureus       Date:  2021-04-12

10.  Dual infection with Ehrlichia chaffeensis and a spotted fever group rickettsia: a case report.

Authors:  D J Sexton; G R Corey; C Carpenter; L Q Kong; T Gandhi; E Breitschwerdt; B Hegarty; S M Chen; H M Feng; X J Yu; J Olano; D H Walker; S J Dumler
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.